Get the Stockscreener App
5.36
3.68%
0.19
After Hours:
5.34
-0.02
-0.37%
Upstream Bio Inc stock is traded at $5.36, with a volume of 429.11K.
It is up +3.68% in the last 24 hours and down -25.35% over the past month.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).
See More
Previous Close:
$5.17
Open:
$5.2
24h Volume:
429.11K
Relative Volume:
0.74
Market Cap:
$293.57M
Revenue:
$3.32M
Net Income/Loss:
$-156.76M
P/E Ratio:
-1.8471
EPS:
-2.9019
Net Cash Flow:
$-140.13M
1W Performance:
+0.37%
1M Performance:
-25.35%
6M Performance:
-43.40%
1Y Performance:
-67.14%
1-Day Range:
$5.07
$5.39
1-Week Range:
$4.985
$5.56
52-Week Range:
$4.985
$33.68
Upstream Bio Inc Stock (UPB) Company Profile
Name
Upstream Bio Inc
Sector
Industry
Phone
781-208-2466
Address
890 WINTER STREET, SUITE 200, WALTHAM
Compare UPB vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
5.36 | 293.57M | 3.32M | -156.76M | -140.13M | -2.9019 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-18-25 | Initiated | Mizuho | Outperform |
| Nov-18-25 | Initiated | Evercore ISI | Outperform |
| Oct-14-25 | Initiated | Truist | Buy |
| Nov-05-24 | Initiated | JP Morgan | Overweight |
| Nov-05-24 | Initiated | Piper Sandler | Overweight |
| Nov-05-24 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Initiated | William Blair | Outperform |
View All
Upstream Bio Inc Stock (UPB) Latest News
Houghton Adam Disposes of 700 Upstream Bio Shares at $5.49 Each - Kalkine Media
Upstream Bio, Inc. (UPB) Stock Analysis: Exploring a 486% Potential Upside in the Biotech Sector - directorstalkinterviews.com
Upstream Bio (UPB) exec offloads shares to cover taxes - stocktitan.net
Upstream Bio Inc (UPB) Stock Price Target & Forecast - TradingKey
Why Did UPB Stock Plunge 40% Today? - Stocktwits
Upstream Bio (UPB) Shares Rise on Promising Trial Data, Despite High Price-to-Sales Ratio - GuruFocus
Upstream Bio Presents Results From The Phase 2 VALIANT Trial Of Verekitug For The Treatment Of Severe Asthma - marketscreener.com
A quarterly dose cut asthma flare-ups 56% versus a dummy treatment. Upstream Bio plans Phase 3 trials. - Stock Titan
Upstream Bio to present phase 2 VALIANT trial data on verekitug for severe asthma at ERS 2026 - Traders Union
Should I Buy UPB? UPB 2026 AnalysisIntellectia AI™ - Intellectia AI
Upstream Bio, Inc. (NASDAQ: UPB) Share Price, UPB Stock News, UPB Share Price & Updates - Kalkine
Analysts Are Bullish on These NA Stocks: Upstream Bio, Inc. (UPB), Fervo Energy Company Class A (FRVO) - The Globe and Mail
Upstream Bio Outlines Phase 3 Plans for Verekitug - TipRanks
Upstream Bio on Track to Begin Two Phase 3 Verekitug Trials in Q1 2027 - marketscreener.com
Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP - GlobeNewswire
UPB Q2 2026 Earnings: Narrower-than-Expected Loss Delivers 5.03% EPS SurpriseStrong Earnings Momentum - vinanet.vn
Upstream Bio Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Norges Bank Initiates New Position in Upstream Bio Inc (UPB) with 4.2 Million Share Purchase - GuruFocus
UPB Q1 2026 Earnings: Narrower Net Loss Beats Consensus as Pipeline Execution Takes Center StageManagement Tone Analysis - vinanet.vn
UPB Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline in Early-Stage PipelineMargin Compression Risk - vinanet.vn
Walleye Capital LLC Invests $3.45 Million in Upstream Bio, Inc. $UPB - MarketBeat
Upstream Bio (NASDAQ:UPB) Lowered to "Strong Sell" Rating by Wall Street Zen - MarketBeat
Upstream Bio (NASDAQ:UPB) Given New $9.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Q3 EPS Estimates for Upstream Bio Decreased by HC Wainwright - MarketBeat
Marie Sanchirico takes charge of Medical Affairs at Upstream Bio, Inc. to drive physician engagement - Traders Union
Truist Financial Maintains UpStream Bio(UPB.US) With Buy Rating, Maintains Target Price $25 - Moomoo
H.C. Wainwright Maintains UpStream Bio(UPB.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Upstream Bio (UPB) Slides 2.54% as Biotech Caution Persists: Key Levels to WatchInstitutional Buy Signals - Vinanet
A Quick Look at Today's Ratings for UpStream Bio(UPB.US), With a Forecast Between $19 to $36 - Moomoo
Truist Financial Maintains UpStream Bio(UPB.US) With Buy Rating, Cuts Target Price to $25 - Moomoo
Upstream Bio Targets Q1 2027 Start for Phase - Minichart
Upstream Bio (NASDAQ:UPB) Announces Quarterly Earnings Results, Beats Expectations By $0.05 EPS - MarketBeat
Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
UPB: Verekitug demonstrated robust efficacy and safety, advancing to Phase 3 for severe asthma and CRSWNP - TradingView
Upstream Bio posts corporate presentation highlighting verekitug Phase 3 plans in severe asthma, CRSwNP - Bitget
Pstream Bio stock rises 2.6% after Q2 results and pipeline update - Traders Union
Form 8K Upstream Bio Inc For: 11 August By Investing.com - Investing.com Canada
Upstream Bio, Inc. 2Q 2026: Revenue $0.8M, EPS $(0.73) — 10-Q Summary - TradingView
Upstream Bio (UPB) deepens R&D spend but ends quarter with $261M cash - Stock Titan
Upstream Bio Q2 net loss narrows slightly on lower R&D costs - TradingView
Upstream Bio reports Q2 2026 net loss $39.7M, cash and short-term investments $261.3M - TradingView
Upstream Bio Posts $39.7 Million Q2 Net Loss as Trials Advance - Quiver Quantitative
Upstream Bio, Inc. sets Phase 3 trial for sever asthma and CRSwNP in Q1 2027 - Traders Union
Upstream Bio (NASDAQ: UPB) reports Q2 2026 loss and advances Phase 3 plans - Stock Titan
Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress - Caledonian Record
Upstream Bio Inc (UPB) Stock News Today - TradingKey
Upstream Bio, Inc. (UPB) Stock Analysis: A Hidden Gem in Biotechnology with a 456% Potential Upside - DirectorsTalk Interviews
Arrowstreet Capital Limited Partnership Buys New Holdings in Upstream Bio, Inc. $UPB - MarketBeat
BlackRock, Inc. Trims Stake in Upstream Bio Inc (UPB) Amid Clini - GuruFocus
Upstream Bio, Inc. (NASDAQ:UPB) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Upstream Bio (UPB) Gains Ground: Testing Key Resistance Levels After 2.5% AdvanceATR Trailing Stop - siam.in
Upstream Bio Inc Stock (UPB) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):